China channel feed – Endpoints News

China channel feed

Astellas licenses Claudin18.2 ADC from China’s Evopoint Biosciences

2 days ago

TCG's R&D venture team makes a T cell engager deal with Shanghai biotech

4 days ago

Pfizer joins PD-1xVEGF race with $1.25B upfront to Chinese biotech 3SBio

Last week

Updated: Merck KGaA continues US tariff surcharge but at a 'decreased' rate

3 weeks ago

Hengrui, one of China's leading biotechs, anticipates $1.2B in proposed Hong Kong listing

3 weeks ago

Early bits of in vivo CAR-T human data emerge from biotech trials in China

4 weeks ago

Pfizer CEO Bourla suggests pharma tariffs will focus on US adversaries, not allies

Last month

AstraZeneca, Novartis execute ‘US for US’ strategy as pharma tariffs near

Last month

AstraZeneca posts another Truqap study fail, says China import tax could triple

Last month

WuXi AppTec sees growth after 2024 dip, plans ‘lean’ operations to temper ‘external opportunities’

Last month

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

Last month

Drugmakers see a substantial, but manageable, hit to business from tariffs. But the worst may lie ahead

Last month

Thermo Fisher buckles up for US-China trade war, budgets $2B to ease impact

Last month

Merck’s Gardasil sales sink further amid China market pressure

Last month

China’s biotech market is staging a comeback that US biotech can only wish for

Last month

Drugmakers stockpile inventory in the US, seeking to get ahead of Trump tariffs

Last month

China startup injects CRISPR therapy into the brain for the first time

Last month

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

Last month

BioNTech-backed ADC maker DualityBio plans IPO on Hong Kong exchange

Last month

Amid Trump’s research cuts, commission says US risks losing biotech race without $15B investment

Last month

ADC startup DualityBio seeks Hong Kong IPO amid precarious market

Last month

China's retaliatory tariffs on US could mean more headwinds for drugmakers

Last month

F-star management takes company private, two years after $161M cash exit to Sino's invoX

Last month

WuXi Biologics’ licensing deals help offset Biosecure threat in the US

2 months ago

12 3 4 Next page Last page